NGC Update Service: November 2, 2015 || U.S. Food and Drug Administration (FDA) Advisories

NGC Update Service: November 2, 2015

U.S. Food and Drug Administration (FDA) Advisories

• October 22, 2015: Kayexalate (sodium polystyrene sulfonate): FDA is requiring the Kayexalate manufacturer to conduct studies to investigate Kayexalate's potential to bind to other medications administered by mouth – drug interactions that could affect how well the other medications work.
• October 22, 2015: Hepatitis C Treatments Viekira Pak and Technivie: FDA is warning that hepatitis C treatments Viekira Pak and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. As a result, FDA is requiring the manufacturer to include information about serious liver injury adverse events to the Contraindications, Warnings and Precautions, Postmarketing Experience, and Hepatic Impairment sections of the Viekira Pak and Technivie drug labels.